Ashkan Emadi

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells
    Ashkan Emadi
    Johns Hopkins University, School of Medicine, Department of Internal Medicine, Division of Hematology, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Bioorg Med Chem 19:7057-62. 2011
  2. doi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
  3. doi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
  4. doi Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A
    Ashkan Emadi
    Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Hematol 85:264-70. 2010
  5. pmc Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
  6. ncbi Diagnosis and management of venous thromboembolism: an update a decade into the new millennium
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:341-51. 2011
  7. doi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
  8. pmc Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity
    Ashley E Ross
    Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    BJU Int 108:447-54. 2011
  9. pmc Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2
    Rena G Lapidus
    Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Pharmaceuticals (Basel) 9:. 2016
  10. doi Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia
    Ashkan Emadi
    University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA Electronic address
    Leuk Res 39:719-29. 2015

Collaborators

Detail Information

Publications24

  1. pmc Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells
    Ashkan Emadi
    Johns Hopkins University, School of Medicine, Department of Internal Medicine, Division of Hematology, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Bioorg Med Chem 19:7057-62. 2011
    ..These results also suggest that dimeric naphthoquinones may be used to selectively target cancer cells that depend on oxidative phosphorylation for energy production and macromolecular synthesis...
  2. doi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
    ....
  3. doi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
    ..We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases...
  4. doi Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A
    Ashkan Emadi
    Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Hematol 85:264-70. 2010
    ..There is high-grade evidence that most, but not all, clinical laboratories test for FVL and prothrombin G20210A accurately...
  5. pmc Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
    ..The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed...
  6. ncbi Diagnosis and management of venous thromboembolism: an update a decade into the new millennium
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:341-51. 2011
    ..The purpose of the current paper is to review the pathogenesis and epidemiology of venous thromboembolism as well as an evidence-based approach to the diagnosis and management of venous thromboembolism...
  7. doi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
    ..Testing for genetic risks for venous thromboembolism (VTE) is common, but the safety and utility of such testing need review...
  8. pmc Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity
    Ashley E Ross
    Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    BJU Int 108:447-54. 2011
    ..To evaluate the cytotoxicity of dimeric naphthoquinones (BiQs) in prostate cancer cells. • To assess the interaction of dimeric naphthoquinones with common therapies including radiation and docetaxel...
  9. pmc Hydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2
    Rena G Lapidus
    Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Pharmaceuticals (Basel) 9:. 2016
    ..Further studies are warranted to better understand this class of potential chemotherapeutics. ..
  10. doi Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia
    Ashkan Emadi
    University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA Electronic address
    Leuk Res 39:719-29. 2015
    ..These data suggest that targeting cellular redox balance in leukemia may provide a therapeutic option for AML patients with relapsed/refractory disease. ..
  11. pmc A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast
    Ashkan Emadi
    Department of Internal Medicine and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 5:e10846. 2010
    ..In order to gain insight into the mode of action of binaphthoquinones we performed a systematic high-throughput screen in a yeast isogenic deletion mutant array for enhanced or suppressed growth in the presence of binaphthoquinones...
  12. ncbi Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms
    Shahab Babakoohi
    Marlene and Stewart Greenebaum Cancer Center, University of Maryland, School of Medicine, Baltimore, MD Medical College of Wisconsin, Milwaukee, WI
    Appl Immunohistochem Mol Morphol . 2016
    ..2-HG and MRS can be utilized for monitoring treatment response in a variety of neoplasms...
  13. doi Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells
    Brandon A Carter-Cooper
    University of Maryland School of Medicine, Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States
    Bioorg Med Chem Lett 27:6-10. 2017
    ..Bis-dimethylamine BiQ, as the isostere of bis-aziridinyl BiQ but without the alkylating moiety did not show as potent anti-AML activity. Systemic administration of bis-aziridinyl BiQ was well tolerated in NSG mice...
  14. doi Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia
    Ashkan Emadi
    School of Medicine, Department of Internal Medicine, University of Maryland Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
    Am J Hematol 90:E77-9. 2015
    ..2 when compared to patients without an IDH mutation (95%CI: 1.3-150.4). IDH1 and IDH2 mutations may predict a favorable response to DNMTI in patients with AML...
  15. doi Asparaginase in the treatment of non-ALL hematologic malignancies
    Ashkan Emadi
    Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, 22 S Greene Street, S9D04C, Baltimore, MD, 21201, USA
    Cancer Chemother Pharmacol 73:875-83. 2014
    ....
  16. doi Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
    Ashkan Emadi
    University of Maryland, School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Md Electronic address
    Exp Hematol 42:247-51. 2014
    ....
  17. doi Management of acquired thrombophilic disorders in 2011: focus on heparin-induced thrombocytopenia, antiphospholipid syndrome, myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:401-11. 2011
    ....
  18. pmc Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
    Ashkan Emadi
    School of Medicine, Marlene and amp Stewart Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Room N9E24, Baltimore, MD 21201, USA
    Pharmaceuticals (Basel) 9:. 2016
    ..In conclusion, asparaginase-containing regimens, which are approved for treatment of acute lymphoblastic leukemia (ALL) but not AML, can be used to treat patients with AML who do not accept blood transfusion. ..
  19. pmc A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone
    Lakshmi Swarna Mukhi Pidugu
    Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA
    BMC Struct Biol 16:1. 2016
    ..We subsequently identified the oxidoreductase NAD(P)H dehydrogenase, quinone 1 (NQO1) as the major target of dimeric naphthoquinones and proposed a mechanism of action that entailed induction of a futile redox cycling...
  20. doi Diseases at the crossroads: chronic myelogenous leukemia and tuberculosis
    Vishal Bhatnagar
    Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore
    Arch Iran Med 18:65-8. 2015
    ..As prevalence of CML increases worldwide, patients with concomitant CML and TB will be seen more often by physicians in all continents, and development of guidelines on simultaneous management of these conditions is imperative. ..
  21. doi Schistocytes, echinocytes, iron deficiency anemia, and thrombocytopenia - hematologic manifestations of splenic angiosarcoma
    Paula Rosenblatt
    University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Baltimore, USA
    Arch Iran Med 16:602-5. 2013
    ..We present a literature review on the hematologic manifestations that is associated with this malignant disease. ..
  22. pmc The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
    Ashkan Emadi
    University of Maryland, School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Leukemia and Hematologic Malignancies, Baltimore, MD 21201, USA
    Pharmacogenomics 13:1257-69. 2012
    ....
  23. pmc Vitamin and mineral supplements: do we really need them?
    Farin Kamangar
    Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD, USA
    Int J Prev Med 3:221-6. 2012
    ..Indeed, some studies have shown increased risk of cancers in relation to using certain vitamins...
  24. pmc Ruthenium-based chemotherapeutics: are they ready for prime time?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 66:1-9. 2010
    ....